NCT00471003已完成不适用
A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 5,448
- 主要终点
- Efficacy and safety of the treatment with telmisartan reported by the physician
研究概览
简要总结
The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age over 18
- •Untreated or ineffectively treated arterial hypertension
排除标准
- •Cholestatic disorders and severe hepatic failure
- •Allergy to telmisartan
- •Pregnancy and lactation period
研究组 & 干预措施
Arm 1
干预措施: Pritor (Telmisartan , BAY68-9291) (Drug)
结局指标
主要结局
Efficacy and safety of the treatment with telmisartan reported by the physician
时间窗: At the both of planned control visits. (Approx. interval between visits 3 months)
次要结局
- Changes in metabolic parameters in telmisartan treated patients(At the both of planned control visits. (Approx. interval between visits 3 months))
研究者
相似试验
已完成
不适用
Assessment of Compliance With Antihypertensive Telmisartan TherapyHypertensionNCT00470886Bayer3,400
已完成
不适用
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With HypertensionHypertensionNCT02242838Boehringer Ingelheim6,336
已完成
不适用
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential HypertensionHypertensionNCT00638911Boehringer Ingelheim33,247
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)DiabetesDiabetes Mellitus, Type 2NCT02321878Novo Nordisk A/S1,092
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®DiabetesNCT02821052Novo Nordisk A/S1,355